However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

The drug is set to be available on the NHS for weight loss soon, but one expert has flagged some potential risks that come with it.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

WEDNESDAY, May 14, 2025 (HealthDay News) — More U.S. teenagers are getting weight-loss surgery, despite the discovery of new ...

Mar. 24, 2025 — A comprehensive study shows that people with fatty liver disease have almost twice the mortality rate of the general population. They have an increased risk of dying from both ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial. The Fox Medical Team's Dr. Mike Cirigliano joined Good Day to take a look ...

Wegovy, a highly effective medication used to treat obesity, shows promise in treating a serious form of liver disease in a ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...